Grace Therapeutics, Inc. (GRCE)
NASDAQ: GRCE · Real-Time Price · USD
2.060
-0.010 (-0.48%)
Oct 5, 2026, 4:00 PM EDT - Market closed
Grace Therapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
5
Market Cap
43.33M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2026 | - | - | - |
| Mar 31, 2025 | - | - | - |
| Mar 31, 2024 | - | - | - |
| Mar 31, 2023 | - | - | - |
| Mar 31, 2022 | - | - | - |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| BioStem Technologies | 34.59M |
| Werewolf Therapeutics | 21.00M |
| Veru Inc. | 16.89M |
| CervoMed | 331.30K |
| Impact BioMedical | 35.00K |
GRCE News
- 6 days ago - ACS Technologies and the Evangelical Lutheran Church in America Expand Strategic Partnership to Deliver a Connected Ministry Experience - Business Wire
- 11 days ago - Vanco, ACS Technologies, and GCFA Strengthen Partnership Through Expanded Ministry Ecosystem - Business Wire
- 21 days ago - Grace Therapeutics Slides: Corporate presentation - Filings
- 4 weeks ago - Grace Therapeutics to Participate in the H.C. Wainright 28th Annual Global Investment Conference - GlobeNewsWire
- 6 weeks ago - Grace Therapeutics files to sell 4.76M shares of common stock for holders - TheFly
- 6 weeks ago - Grace Therapeutics Registration statement: Registration filing - Filings
- 7 weeks ago - Grace Therapeutics Announces First Quarter 2027 Financial Results, Provides Business Update - GlobeNewsWire
- 7 weeks ago - Grace Therapeutics Quarterly report: Q1 2027 - Filings